SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma.
Anstadt EJ, Carmona R, Berlin E, Yegya-Raman N, Venigalla S, Reddy V, Williams GR, Leibensperger MR, Wojcieszynski A, Baumann BC, Lee MK, Plastaras JP, Furth EE, Mell LK, Metz JM, Ben-Josef E.
Anstadt EJ, et al. Among authors: ben josef e.
Cancer. 2024 Feb 1;130(3):476-484. doi: 10.1002/cncr.35058. Epub 2023 Oct 12.
Cancer. 2024.
PMID: 37823514